Project title: Lead optimisation of novel inhibitors of IRAP for the treatment of fibrosis in diabetes-induced renal and cardiovascular disease
Inosi Therapeutics has developed novel inhibitors of Insulin Regulated Aminopeptidase (IRAP) for the resolution of renal and cardiac fibrotic conditions associated with diabetes.
Traditional diabetic treatments normalise blood glucose levels, but are not effective in stopping or reversing diabetes-induced renal and cardiac disease, with approximately 50% of patients still developing these conditions leading to end-stage organ failure and death. Multiple mechanisms underlie the development of diabetes-induced organ dysfunction, including chronic inflammation, oxidative stress and fibrosis, contributing to the difficulty in finding an effective treatment.
The Inosi research team has identified a novel target, Insulin Regulated Aminopeptidase (IRAP) and its association with fibrosis and inflammation in both human and preclinical models of cardiovascular and renal disease. Novel, specific inhibitors of IRAP developed by Inosi target multiple arms of the processes involved in chronic kidney and cardiovascular disease and are effective in reversing established fibrosis and inflammation in both diabetic and age-induced preclinical models.
This TTRA supported project aims to optimise this new lead series of IRAP inhibitors to meet the criteria for an orally-available drug candidate to bring to clinical trials as a first-in-class treatment for diabetes-related renal and cardiac fibrotic disease.
TTRA Project Round: One
- Investors: IP Group, Monash Innovation
- Lead Research: Monash Institute of Pharmaceutical Sciences, Monash Biomedicine Discovery Institute
- Originating IP: Monash University, University of Melbourne's St Vincent's Institute of Medical Research and the Florey Institute of Neuroscience and Mental Health
- TTRA: $704,230
- Industry Contribution: $786,095.60 cash, $539,898.76 in-kind
Duration: October 2021 – November 2023